P Van Damme

Universitaire Instelling Antwerpen (Belgium) 
Public Health, General Economics
"P Damme"
Cross-listing: PHTree

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Vorsters A, Van Keer S, Van Damme P. (2015) The use of urine in the follow-up of HPV vaccine trials. Human Vaccines & Immunotherapeutics. 11: 350-2
Arbyn M, Broeck DV, Benoy I, et al. (2015) Surveillance of effects of HPV vaccination in Belgium Cancer Epidemiology
Kanitz EE, Wu LA, Giambi C, et al. (2012) Variation in adult vaccination policies across Europe: An overview from VENICE network on vaccine recommendations, funding and coverage Vaccine. 30: 5222-5228
Goeyvaerts N, Hens N, Theeten H, et al. (2012) Estimating vaccination coverage for the trivalent measles-mumps-rubella vaccine from trivariate serological data. Statistics in Medicine. 31: 1432-49
Van Damme P, Zanetti AR, Shouval D, et al. (2010) Strategies for global prevention of hepatitis B virus infection. Advances in Experimental Medicine and Biology. 659: 175-88
Goeyvaerts N, Hens N, Ogunjimi B, et al. (2010) Estimating infectious disease parameters from data on social contacts and serological status Journal of the Royal Statistical Society. Series C: Applied Statistics. 59: 255-277
Vandermeulen C, Clement F, Roelants M, et al. (2009) Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination Journal of Infectious Diseases. 199: 1457-1460
Effelterre TV, Shkedy Z, Aerts M, et al. (2009) Contact patterns and their implied basic reproductive numbers: an illustration for varicella-zoster virus. Epidemiology and Infection. 137: 48-57
Fitzsimons D, François G, Hall A, et al. (2005) Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 23: 4158-66
Tjalma WAA, Damme PV. (2005) Is the public enough aware to accept a vaccination program against human papillomavirus? [2] Vaccine. 23: 3231
See more...